Corporate Controller, Beacon Biosignals

$170-190k

Excel
Quickbooks
Senior and Expert level
Boston
Remote from US
Beacon Biosignals

AI brain monitoring

Open for applications

Beacon Biosignals

AI brain monitoring

101-200 employees

HealthcareB2BArtificial IntelligenceMachine LearningMedTech

Open for applications

$170-190k

Excel
Quickbooks
Senior and Expert level
Boston
Remote from US

101-200 employees

HealthcareB2BArtificial IntelligenceMachine LearningMedTech

Company mission

To improve human health by enabling rapid, targeted interventions through advanced brain analytics.

Company mission

To improve human health by enabling rapid, targeted interventions through advanced brain analytics.

Top investors

40% employee growth in 12 months

Our take

The brain has long been considered one of the most mysterious fields of medicine - and psychiatric and neurological diseases therefore one of the least understood. Better access to real-time brain data, however, could change this and that’s exactly what Beacon Biosignals is hoping to deliver.

Beacon Biosignals has developed an AI-powered EEG platform designed to better measure and understand brain activity. Its technology includes a lightweight wearable headband that tracks brain signals during sleep and at home, feeding huge amounts of real-world data into machine-learning models. The aim is to help researchers analyze brain activity faster, identify new biomarkers, and improve the development of treatments for neurological and psychiatric disorders.

The company recently raised major funding and acquired home sleep testing specialist CleveMed as it expands its AI-powered brain health platform. Its FDA-cleared wearable headband is already being used in more than 40 clinical trails studying conditions like depression, Alzheimer's, Parkinson's, and sleep disorders. By collecting millions of hours of brain activity data, Beacon hopes to help researchers detect diseases earlier and better understand how the brain changes over time.

Kirsty headshot

Kirsty

Company Specialist at Welcome to the Jungle

Funding (last 2 of 5 rounds)

Apr 2026

$11m

SERIES B

Nov 2025

$86m

SERIES B

Total funding: $127.5m

This company has top investors

Leadership

Jarrett Revels

(Co-Founder & CTO)

Prior to co-founding Beacon Biosignals in 2019, Jarrett spent 4 years at Massachusetts Institute of Technology, joining as a Scientific Programmer before become a Performance Engineer then Research Software Developer.

Jacob Donoghue

(Co-Founder & CEO)

Jacob completed a Neuroscience PhD at Massachusetts Institute of Technology, and received his MD from Harvard Medical School. Subsequently they carried out research for Cyberkinetics Neurotechnology Systems and Massachusetts General Hospital.

Brandon Westover

(Co-Founder)

Received their MD from Washington University School of Medicine, then took up a Neurology residency at Harvard Medical School. Alongside their work at Beacon Biosignals, Brandon is also an HST Faculty member at MIT and a Neurologist/Medical AI Researcher at Massachusetts General Hospital.

Syd Cash

(Co-Founder)

Syd is an Associate Professor at Harvard Medical School, who also leads the Center for Neurotechnology and Neurorecovery at MGH.